Inhibrx Biosciences, Inc. INBX Clinical drug substance and product manufacturing
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inhibrx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing?
- Inhibrx Biosciences, Inc. (INBX) reported clinical drug substance and product manufacturing of $2.14M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing changed year-over-year?
- Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing decreased by 75.3% year-over-year, from $8.68M to $2.14M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s clinical drug substance and product manufacturing has grown at a -50.7% compound annual growth rate (CAGR), from $22.81M to $5.54M.